The use of inositol in patients with menopausal syndrome

Lapina I.A., Dobrokhotova Yu.E., Chirvon T.G., Nikitenko Ya.A., Kolganova E.A.

1) N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia; 2) JSC Group of companies MEDSI, Moscow, Russia

Menopausal hormone therapy (MHT) has been the most effective method for relieving menopausal symptoms and menopausal disorders for many years. Despite the fact that modern research confirms the safety of this therapy, there are absolute and relative contraindications for its use. In addition, a significant number of patients continue to refuse to take MHT. In this regard, the search for non-hormonal alternative treatment methods is a relevant issue.
Objective: To evaluate the effect of taking a combination of  myoinositol and D-chiroinositol in the ratio of 5:1, folic acid (Dikirogen) and manganese on the course of menopausal syndrome of mild to moderate severity in patients in early postmenopausal period.
Materials and methods: A prospective study included 84 women in early postmenopausal period with mild to moderate menopausal syndrome. They were divided into three groups: group 1 consisted of patients with metabolic syndrome and BMI of more than 25 kg/m² (stage 1–2 overweight or obesity); group 2 (n=28) included lean patients without metabolic disorders with BMI of less than 25 kg/m². In these two groups, the patients took a combined medication containing myoinositol and D-chiroinositol in the ratio of 5:1, manganese and folic acid (in a dosage of 1,000 mg+200 mg+5 mg+20 mcg), one sachet twice a day for six months. Group 3 (control group) consisted of 30 patients who did not receive therapy and they were divided into two subgroups: subgroup 3A (n=14) included women with metabolic syndrome and BMI of more than 25 kg/m2 (stage 1–2 overweight or obesity), subgroup 3B (n=16) included lean patients without metabolic disorders with BMI of less than 25 kg/m². Before starting therapy and after 6 months of taking the medication, patients’ complaints and parameters of lipid and carbohydrate metabolism were evaluated.
Results: Therapy with the combined medication containing myoinositol and D-chiroinositol in the ratio of 5:1, manganese and folic acid contributed to a statistically significant decrease in the severity of menopausal disorders (the average value on the Greene Climacteric Scale lowered from 35 to 11 scores), a decrease in total cholesterol by 19.5%, triglycerides by 42.5%, fasting glucose by 19%, BMI by 10.9%, and waist circumference by 4.6% in group 1 that included patients with metabolic disorders. There were no statistically significant results after therapy (p>0.05) and there was no improvement in menopausal symptoms in group 2 which consisted of women with normal BMI.
Conclusion: Taking Dikirogen has been shown to reduce the severity of menopausal disorders in patients in the early postmenopausal period who have metabolic syndrome and obesity. In patients with normal body weight, no clinical effect was observed on menopausal and metabolic disorders.

Authors’ contributions: Lapina I.A., Dobrokhotova Yu.E., Chirvon T.G. – study concept and design, statistical data processing; Chirvon T.G., Nikitenko Ya.A., Kolganova E.A. – collection and processing of material, writing the text; Lapina I.A. – editing.
Conflicts of interest. Authors declare lack of the possible conflicts of interests.
Funding. The study was conducted without sponsorship.
Ethics approval. The study was approved by the Ethical Review Board of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia (protocol No. 251 of May 19, 2025).
Patients’ consent to publication. The patients provided an informed consent for the publication of their data.
Research data exchange. The data confirming the conclusions of this study are available upon request from the author responsible for the correspondence after the approval of the lead researcher.
For citation: Lapina I.A., Dobrokhotova Yu.E., Chirvon T.G., Nikitenko Ya.A., Kolganova E.A. 
The use of inositol in patients with menopausal syndrome.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (6): 155-162 (in Russian)
https://dx.doi.org/10.18565/aig.2025.155

Keywords

References

About the Authors

Irina A. Lapina, Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health of Russia, 117513, Russia, Moscow, Ostrovityanov str., 1, doclapina@mail.ru, eLibrary SPIN: 1713-6127, https://orcid.org/0000-0002-2875-6307
Yulia E. Dobrokhotova, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University,
Ministry of Health of Russia, 117513, Russia, Moscow, Ostrovityanov str., 1, Pr.Dobrohotova@mail.ru, eLibrary SPIN: 2925-9948, https://orcid.org/0000-0002-7830-2290
Tatiana G. Chirvon, PhD, Teaching Assistant at the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health
of Russia, 117513, Russia, Moscow, Ostrovityanov str., 1, +7(916)341-68-24, tkoltinova@gmail.com, eLibrary SPIN: 9582-1650, https://orcid.org/0000-0002-8302-7510
Yana A. Nikitenko, obstetrician-gynecologist, Head of the Department of Outpatient Gynecology, CDC MEDSI on Solyanka, gorbarskaya@gmail.com,
https://orcid.org/0009-0000-4908-555X
Elina A. Kolganova, 4th year student of IKM, Pirogov Russian National Research Medical University, Ministry of Health of Russia,
117513, Russia, Moscow, Ostrovityanov str., 1, elinakolganova36@gmail.com, https://orcid.org/0009-0003-7176-2926
Corresponding author: Tatiana G. Chirvon, tkoltinova@gmail.com

Similar Articles